Pillar Pacific Capital Management buys $9,215,723 stake in Amgen (AMGN)

Amgen (AMGN) : Pillar Pacific Capital Management scooped up 2,616 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 53,138 shares of Amgen which is valued at $9,215,723.Amgen makes up approximately 1.48% of Pillar Pacific Capital Management’s portfolio.

Other Hedge Funds, Including , Thompson Investment Management boosted its stake in AMGN in the latest quarter, The investment management firm added 9 additional shares and now holds a total of 27,687 shares of Amgen which is valued at $4,801,756. Amgen makes up approx 0.94% of Thompson Investment Management’s portfolio.Meyer Handelman Co boosted its stake in AMGN in the latest quarter, The investment management firm added 850 additional shares and now holds a total of 175,423 shares of Amgen which is valued at $29,062,328. Amgen makes up approx 1.27% of Meyer Handelman Co’s portfolio.Atwood Palmer Inc reduced its stake in AMGN by selling 200 shares or 1.43% in the most recent quarter. The Hedge Fund company now holds 13,781 shares of AMGN which is valued at $2,283,098. Amgen makes up approx 0.40% of Atwood Palmer Inc’s portfolio.Ct Financial Advisors boosted its stake in AMGN in the latest quarter, The investment management firm added 550 additional shares and now holds a total of 14,481 shares of Amgen which is valued at $2,332,889. Amgen makes up approx 1.46% of Ct Financial Advisors’s portfolio.

Amgen closed down -0.76 points or -0.44% at $172.67 with 21,22,162 shares getting traded on Thursday. Post opening the session at $173.3, the shares hit an intraday low of $172.04 and an intraday high of $173.67 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Investors should note that on Jul 22, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced Aug 15, 2016 as the ex-dividend date and fixed the record date on Aug 17, 2016. The payable date has been fixed on Sep 8, 2016.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.